307 related articles for article (PubMed ID: 33288862)
1. Midostaurin after allogeneic stem cell transplant in patients with FLT3-internal tandem duplication-positive acute myeloid leukemia.
Maziarz RT; Levis M; Patnaik MM; Scott BL; Mohan SR; Deol A; Rowley SD; Kim DDH; Hernandez D; Rajkhowa T; Haines K; Bonifacio G; Rine P; Purkayastha D; Fernandez HF
Bone Marrow Transplant; 2021 May; 56(5):1180-1189. PubMed ID: 33288862
[TBL] [Abstract][Full Text] [Related]
2. Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 Mutation.
Stone RM; Mandrekar SJ; Sanford BL; Laumann K; Geyer S; Bloomfield CD; Thiede C; Prior TW; Döhner K; Marcucci G; Lo-Coco F; Klisovic RB; Wei A; Sierra J; Sanz MA; Brandwein JM; de Witte T; Niederwieser D; Appelbaum FR; Medeiros BC; Tallman MS; Krauter J; Schlenk RF; Ganser A; Serve H; Ehninger G; Amadori S; Larson RA; Döhner H
N Engl J Med; 2017 Aug; 377(5):454-464. PubMed ID: 28644114
[TBL] [Abstract][Full Text] [Related]
3. Midostaurin in combination with chemotherapy is most effective in patients with acute myeloid leukemia presenting with high FLT3-ITD allelic ratio who proceed to allogeneic stem cell transplantation while in first complete remission.
Ofran Y; Leiba R; Frisch A; Horesh N; Henig I; Yehudai-Ofir D; Moshe Y; Neaman M; Ganzel C; Gal-Rabinovich K; Hellmann I; Weinstein V; Berger T; Wolach O
Eur J Haematol; 2021 Jan; 106(1):64-71. PubMed ID: 32949053
[TBL] [Abstract][Full Text] [Related]
4. Midostaurin: A New Oral Agent Targeting FMS-Like Tyrosine Kinase 3-Mutant Acute Myeloid Leukemia.
Stansfield LC; Pollyea DA
Pharmacotherapy; 2017 Dec; 37(12):1586-1599. PubMed ID: 28976600
[TBL] [Abstract][Full Text] [Related]
5. Sorafenib Maintenance After Allogeneic Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia With
Burchert A; Bug G; Fritz LV; Finke J; Stelljes M; Röllig C; Wollmer E; Wäsch R; Bornhäuser M; Berg T; Lang F; Ehninger G; Serve H; Zeiser R; Wagner EM; Kröger N; Wolschke C; Schleuning M; Götze KS; Schmid C; Crysandt M; Eßeling E; Wolf D; Wang Y; Böhm A; Thiede C; Haferlach T; Michel C; Bethge W; Wündisch T; Brandts C; Harnisch S; Wittenberg M; Hoeffkes HG; Rospleszcz S; Burchardt A; Neubauer A; Brugger M; Strauch K; Schade-Brittinger C; Metzelder SK
J Clin Oncol; 2020 Sep; 38(26):2993-3002. PubMed ID: 32673171
[TBL] [Abstract][Full Text] [Related]
6. Midostaurin plus intensive chemotherapy for younger and older patients with AML and FLT3 internal tandem duplications.
Döhner H; Weber D; Krzykalla J; Fiedler W; Wulf G; Salih H; Lübbert M; Kühn MWM; Schroeder T; Salwender H; Götze K; Westermann J; Fransecky L; Mayer K; Hertenstein B; Ringhoffer M; Tischler HJ; Machherndl-Spandl S; Schrade A; Paschka P; Gaidzik VI; Theis F; Thol F; Heuser M; Schlenk RF; Bullinger L; Saadati M; Benner A; Larson R; Stone R; Döhner K; Ganser A
Blood Adv; 2022 Sep; 6(18):5345-5355. PubMed ID: 35486475
[TBL] [Abstract][Full Text] [Related]
7. Mild chronic graft-versus-host disease may alleviate poor prognosis associated with FLT3 internal tandem duplication for adult acute myeloid leukemia following allogeneic stem cell transplantation with myeloablative conditioning in first complete remission: a retrospective study.
Nasilowska-Adamska B; Czyz A; Markiewicz M; Rzepecki P; Piatkowska-Jakubas B; Paluszewska M; Dzierzak-Mietla M; Solarska I; Borg K; Prochorec-Sobieszek M; Szydlo R; Lewandowski K; Skotnicki A; Jedrzejczak WW; Kyrcz-Krzemien S; Komarnicki M; Warzocha K
Eur J Haematol; 2016 Mar; 96(3):236-44. PubMed ID: 25912052
[TBL] [Abstract][Full Text] [Related]
8. Midostaurin added to chemotherapy and continued single-agent maintenance therapy in acute myeloid leukemia with
Schlenk RF; Weber D; Fiedler W; Salih HR; Wulf G; Salwender H; Schroeder T; Kindler T; Lübbert M; Wolf D; Westermann J; Kraemer D; Götze KS; Horst HA; Krauter J; Girschikofsky M; Ringhoffer M; Südhoff T; Held G; Derigs HG; Schroers R; Greil R; Grießhammer M; Lange E; Burchardt A; Martens U; Hertenstein B; Marretta L; Heuser M; Thol F; Gaidzik VI; Herr W; Krzykalla J; Benner A; Döhner K; Ganser A; Paschka P; Döhner H;
Blood; 2019 Feb; 133(8):840-851. PubMed ID: 30563875
[TBL] [Abstract][Full Text] [Related]
9. Outcome of FLT3-ITD-positive acute myeloid leukemia: impact of allogeneic stem cell transplantation and tyrosine kinase inhibitor treatment.
Fleischmann M; Schnetzke U; Schrenk KG; Schmidt V; Sayer HG; Hilgendorf I; Hochhaus A; Scholl S
J Cancer Res Clin Oncol; 2017 Feb; 143(2):337-345. PubMed ID: 27778197
[TBL] [Abstract][Full Text] [Related]
10. Sorafenib plus intensive chemotherapy improves survival in patients with newly diagnosed, FLT3-internal tandem duplication mutation-positive acute myeloid leukemia.
Sasaki K; Kantarjian HM; Kadia T; Patel K; Loghavi S; Garcia-Manero G; Jabbour EJ; DiNardo C; Pemmaraju N; Daver N; Dalle IA; Short N; Yilmaz M; Bose P; Naqvi K; Pierce S; Yalniz F; Cortes JE; Ravandi F
Cancer; 2019 Nov; 125(21):3755-3766. PubMed ID: 31310323
[TBL] [Abstract][Full Text] [Related]
11. Midostaurin in Combination With Standard Chemotherapy for Treatment of Newly Diagnosed FMS-Like Tyrosine Kinase 3 (FLT3) Mutation-Positive Acute Myeloid Leukemia.
Kim M; Williams S
Ann Pharmacother; 2018 Apr; 52(4):364-369. PubMed ID: 29231051
[TBL] [Abstract][Full Text] [Related]
12. Clonal evolution of acute myeloid leukemia with FLT3-ITD mutation under treatment with midostaurin.
Schmalbrock LK; Dolnik A; Cocciardi S; Sträng E; Theis F; Jahn N; Panina E; Blätte TJ; Herzig J; Skambraks S; Rücker FG; Gaidzik VI; Paschka P; Fiedler W; Salih HR; Wulf G; Schroeder T; Lübbert M; Schlenk RF; Thol F; Heuser M; Larson RA; Ganser A; Stunnenberg HG; Minucci S; Stone RM; Bloomfield CD; Döhner H; Döhner K; Bullinger L
Blood; 2021 Jun; 137(22):3093-3104. PubMed ID: 33598693
[TBL] [Abstract][Full Text] [Related]
13. Sorafenib maintenance in patients with FLT3-ITD acute myeloid leukaemia undergoing allogeneic haematopoietic stem-cell transplantation: an open-label, multicentre, randomised phase 3 trial.
Xuan L; Wang Y; Huang F; Fan Z; Xu Y; Sun J; Xu N; Deng L; Li X; Liang X; Luo X; Shi P; Liu H; Wang Z; Jiang L; Yu C; Zhou X; Lin R; Chen Y; Tu S; Huang X; Liu Q
Lancet Oncol; 2020 Sep; 21(9):1201-1212. PubMed ID: 32791048
[TBL] [Abstract][Full Text] [Related]
14. Clinical and economic analysis of patients with acute myeloid leukemia by FLT3 status and midostaurin use at a Comprehensive Cancer Center.
Willis C; Menon J; Unni S; Au T; Yoo M; Biskupiak J; Brixner D; Ndife B; Joseph G; Bonifacio G; Stein E; Tantravahi S; Shami PJ; Kovacsovics T; Stenehjem D
Leuk Res; 2019 Dec; 87():106262. PubMed ID: 31756575
[TBL] [Abstract][Full Text] [Related]
15. TKI Maintenance After Stem-Cell Transplantation for
Gagelmann N; Wolschke C; Klyuchnikov E; Christopeit M; Ayuk F; Kröger N
Front Immunol; 2021; 12():630429. PubMed ID: 33790903
[TBL] [Abstract][Full Text] [Related]
16. Comparative value of post-remission treatment in cytogenetically normal AML subclassified by NPM1 and FLT3-ITD allelic ratio.
Versluis J; In 't Hout FE; Devillier R; van Putten WL; Manz MG; Vekemans MC; Legdeur MC; Passweg JR; Maertens J; Kuball J; Biemond BJ; Valk PJ; van der Reijden BA; Meloni G; Schouten HC; Vellenga E; Pabst T; Willemze R; Löwenberg B; Ossenkoppele G; Baron F; Huls G; Cornelissen JJ
Leukemia; 2017 Jan; 31(1):26-33. PubMed ID: 27416910
[TBL] [Abstract][Full Text] [Related]
17. Midostaurin reduces relapse in FLT3-mutant acute myeloid leukemia: the Alliance CALGB 10603/RATIFY trial.
Larson RA; Mandrekar SJ; Huebner LJ; Sanford BL; Laumann K; Geyer S; Bloomfield CD; Thiede C; Prior TW; Döhner K; Marcucci G; Voso MT; Klisovic RB; Galinsky I; Wei AH; Sierra J; Sanz MA; Brandwein JM; de Witte T; Niederwieser D; Appelbaum FR; Medeiros BC; Tallman MS; Krauter J; Schlenk RF; Ganser A; Serve H; Ehninger G; Amadori S; Gathmann I; Döhner H; Stone RM
Leukemia; 2021 Sep; 35(9):2539-2551. PubMed ID: 33654204
[TBL] [Abstract][Full Text] [Related]
18. Treatment with midostaurin and other FLT3 targeting inhibitors is associated with an increased risk of cardiovascular adverse events in patients who underwent allogeneic hematopoietic stem cell transplantation with FLT3-mutated AML.
Cremer A; Enssle JC; Pfaff S; Kouidri K; Lang F; Brandts C; Zeiher A; Cremer S; Steffen B; Serve H; Bug G
Ann Hematol; 2023 Oct; 102(10):2903-2908. PubMed ID: 37552323
[TBL] [Abstract][Full Text] [Related]
19. Sorafenib and omacetaxine mepesuccinate as a safe and effective treatment for acute myeloid leukemia carrying internal tandem duplication of Fms-like tyrosine kinase 3.
Zhang C; Lam SSY; Leung GMK; Tsui SP; Yang N; Ng NKL; Ip HW; Au CH; Chan TL; Ma ESK; Yip SF; Lee HKK; Lau JSM; Luk TH; Li W; Kwong YL; Leung AYH
Cancer; 2020 Jan; 126(2):344-353. PubMed ID: 31580501
[TBL] [Abstract][Full Text] [Related]
20. FLT3-ITD Compared with DNMT3A R882 Mutation Is a More Powerful Independent Inferior Prognostic Factor in Adult Acute Myeloid Leukemia Patients After Allogeneic Hematopoietic Stem Cell Transplantation: A Retrospective Cohort Study.
Ardestani MT; Kazemi A; Chahardouli B; Mohammadi S; Nikbakht M; Rostami S; Jalili M; Vaezi M; Alimoghaddam K; Ghavamzadeh A
Turk J Haematol; 2018 Aug; 35(3):158-167. PubMed ID: 29786546
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
